Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 224.00
Bid: 223.00
Ask: 224.00
Change: 1.00 (0.45%)
Spread: 1.00 (0.448%)
Open: 220.00
High: 224.00
Low: 220.00
Prev. Close: 223.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

10 Mar 2020 07:00

RNS Number : 5158F
PureTech Health PLC
10 March 2020
 

10 March 2020

PureTech Health plc

 

Notice of Results

 

PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company") plans to announce its financial results for the year ended 31 December 2019 on Thursday, 9 April 2020.

 

A presentation and conference call for analysts will take place at 2:00pm BST / 9:00am EDT, and a webcast of the presentation will be available on the Company's website at http://puretechhealth.com/investors under the Reports and Presentations tab.

 

PureTech also confirms that the global outbreak of COVID-19 has not adversely affected the Company's business of addressing major diseases through its leadership in immunology and the Brain-Immune-Gut (BIG) Axis. The Company has a very strong cash position and is advancing the business in accordance with its previously announced strategy and timelines while continuing to monitor the situation.

 

About PureTech Health

PureTech is a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's affiliates, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBCGDXUXGDGGC
Date   Source Headline
19th May 20227:00 amRNSTransaction in Own Shares
18th May 20227:00 amRNSTransaction in Own Shares
17th May 202212:00 pmRNSPRTC to Present at UBS Healthcare Conference
17th May 20227:00 amRNSTransaction in Own Shares
16th May 20222:30 pmRNSPRTC Presents LYT-100 Data at ATS Conference
16th May 20227:00 amRNSTransaction in Own Shares
13th May 20227:00 amRNSTransaction in Own Shares
12th May 20227:00 amRNSTransaction in Own Shares
11th May 20227:00 amRNSTransaction in Own Shares
10th May 20227:00 amRNSTransaction in Own Shares
9th May 20227:00 amRNSPRTC Share Buyback Programme Commences Purchases
5th May 20227:00 amRNSPRTC Announces Share Buyback Programme Up to $50M
4th May 202211:35 amRNSGelesis Presents GS200 Weight Loss Data at ECO
3rd May 20227:00 amRNSTotal Voting Rights
29th Apr 202211:05 amRNSGelesis Data: Therapeutic Shows Gut Health Benefit
26th Apr 20227:00 amRNSPRTC Final Results & Publication of Annual Report
13th Apr 20224:44 pmRNSPRTC's Vedanta Publishes VE303 Data
12th Apr 202212:05 pmRNSAkili Depression Data Published in AJP
12th Apr 20227:00 amRNSGlyph: 20x Oral Bioavailability of Buprenorphine
7th Apr 20227:00 amRNSNotice of Results
1st Apr 20227:00 amRNSTotal Voting Rights
24th Mar 20227:00 amRNSPRTC Appoints Merck Vet to BOD & Audit Committee
17th Mar 20221:05 pmRNSAkili Adds Gaming Vet as Chief Product Officer
16th Mar 202210:35 amRNSGelesis: Record-Breaking Plenity Prescriptions
8th Mar 202212:05 pmRNSAkili Named to World's Most Innovative Companies
18th Feb 20224:30 pmRNSHolding(s) in Company
17th Feb 202212:05 pmRNSAkili Data: Enhanced Brain Activity in Kids w/ADHD
15th Feb 20227:00 amRNSPRTC's Akili Files Registration Statement on S-4
10th Feb 202212:00 pmRNSPRTC to Present at Leerink Healthcare Conference
4th Feb 20227:00 amRNSPDMR DEALING - PURCHASE OF SHARES
31st Jan 202211:50 amRNSPRTC's Gelesis Launches Plenity Media Campaign
26th Jan 202212:02 pmRNSPRTC’s Akili to Become Public & $162M Funding
14th Jan 20227:00 amRNSPRTC's Gelesis to Debut on NYSE Today Ticker GLS
7th Jan 202212:00 pmRNSPureTech to Present at JPM Healthcare Conference
6th Jan 20227:00 amRNSLYT-100 Shows Improved AE Profile vs Pirfenidone
5th Jan 202212:05 pmRNSGelesis Adds to BOD & Declared Effective by SEC
20th Dec 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
16th Dec 20217:00 amRNSPRTC Provides Recap Ahead of Catalyst-Rich 2022
8th Dec 202112:00 pmRNSPRTC Presents Data at ACNP Conference For LYT-300
7th Dec 202112:00 pmRNSPRTC's Lymphatic Platform Candidate Human Study
1st Dec 202112:10 pmRNSPRTC: Gelesis' Plenity Now Broadly Available in US
1st Dec 20217:00 amRNSTotal Voting Rights
18th Nov 202112:10 pmRNSPRTC's Gelesis Receives $30M Plenity Order from Ro
16th Nov 202112:00 pmRNSPRTC Publishes Previous LYT-100 MAD Study Results
15th Nov 202112:00 pmRNSPRTC Presents at Two Upcoming Investor Conferences
12th Nov 202112:00 pmRNSPRTC Presents Immunooncology Ph 1/2 Trial at SITC
11th Nov 202112:00 pmRNSFDA Grants PRTC's LYT-200 Orphan Drug Designation
10th Nov 20217:00 amRNSPRTC Receives $100M from Founded Entity Shares
9th Nov 202112:34 pmRNSKRTX and Zai Lab to Develop KarXT in Greater China
9th Nov 20217:00 amRNSPRTC Presents at Jefferies Healthcare Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.